{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"101"}]}],"title":"Participants with At Least 1 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"59"}]}],"title":"Participants with SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"101"}],"units":"Participants"}],"groups":[{"description":"Participants diagnosed with WM with mutated MYD88 gene received 420 mg ibrutinib once daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG000","title":"Arm A: Ibrutinib"},{"description":"Participants diagnosed with WM with mutated MYD88 gene received 160 mg zanubrutinib twice daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG001","title":"Arm B: Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set includes all participants who received any dose of zanubrutinib or ibrutinib","reportingStatus":"POSTED","timeFrame":"Up to approximately 5 years and 5 months","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","type":"SECONDARY","unitOfMeasure":"Number of Participants"}